MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2024 International Congress

    Interim results of a mixed method research-in-action study to evaluate and improve patient and public involvement within the EJS ACT-PD initiative

    M-L. Zeissler, N. Lapelle, S. Collins, E. Cowd, C. Gonzalez-Robles, R. Ellis-Doyle, G. Mills, R. Petty, T. Foltynie, C. Carroll, K. Mcfarthing (Plymouth, United Kingdom)

    Objective: To improve patient and public involvement and engagement (PPIE) within EJS ACT-PD by evaluating members’ perceptions of PPIE through a mixed methods research-in-action study.…
  • 2024 International Congress

    Clinic vs Self-Referral for a Home-Based Fracture Prevention Trial of Zoledronate vs Placebo in Patients with Neurodegenerative Parkinsonism

    C. Tanner, N. Luthra, S. Goldman, R. Zuzuarregui, E. Brown, C. Meng, J. Perkins, T. Hue, C. Schambach, D. Kreisel, D. Young, I. Bledsoe, L. Racelo, P. Nanda Kumar, P. Ranola, M. Schwarzschild, R. Dorsey, A. Espay, S. Krischer, J. Falcon, C. Comella, M. Siddiqui, F. Gao, M. Ledoux, E. Byrd, I. Litvan, N. Mcfarland, K. Mitchell, D. Standaert, J. Beck, K. Williams, M. Drake, D. Bauer, K. Lyles, S. Cummings (SAN FRANCISCO, USA)

    Objective: To evaluate recruitment, eligibility and characteristics of clinic referred vs self-referred patients in the ongoing Trial of Parkinson’s and Zoledronate (TOPAZ, NCT03924414) Background: People…
  • 2024 International Congress

    Overview of Phase 3 Trials of Continuous Subcutaneous Apomorphine Infusion for PD Patients with Motor Fluctuations

    R. Pahwa, T. van Laar, K. Dashtipour, G. Ceresoli-Borroni (Kansas City, USA)

    Objective: Review available efficacy data from Phase 3 studies assessing continuous subcutaneous apomorphine infusion (CSAI) for patients with PD experiencing motor fluctuations. Background: Despite decades…
  • 2024 International Congress

    Exploring the Neuroprotective Potential of Mushroom Extracts in Parkinson’s Disease In-Vitro Models

    FAZ. Dustov, SEO. Seo (Tashkent, Uzbekistan)

    Objective: This study investigates the potential neuroprotective effects of several mushroom extracts in PD in-vitro models. Background: Parkinson's disease, a progressive condition, involves dysfunction or…
  • 2024 International Congress

    Novel In-Clinic Use of Levodopa Inhalation Powder (CVT-301) as an Outpatient Diagnostic Tool for Parkinson’s Disease

    Z. Afshari, N. Nguyen, M. Afshari (Glenview, USA)

    Objective: The clinical diagnosis of PD is based on demonstration of major motor manifestations on the neurologic exam, however, levodopa-responsiveness can be a very helpful…
  • 2024 International Congress

    Real-World Multicenter Analysis of Levodopa Equivalent Daily Dosage Algorithms- Capturing Geographical and Demographic Disparities in Parkinson’s Disease Therapy Spanning Six Countries and Two Continents

    P. Kukkle, L. Kalia, A. Habib, P. Jagota, R. Ojha, R. Kandadai, S. Desai, M. Caldera, D. Sirisena, D. Garg, T. Mestre, R. Neupane, S. Maytharakcheep, K. Sanyawut, R. Borgohain (Bangalore, India)

    Objective: To assess the influence of updated Levodopa Equivalent Daily Dosage (LEDD) conversion factors in capturing the newer therapies in Parkinson’s Disease (PD) and therapy…
  • 2024 International Congress

    Indications of advanced therapies in Parkinson’s Disease: a retrospective study in a Belgian reference center

    B. Delsaut, V. Leclercq, S. Dethy (La Louvière, Belgium)

    Objective: The aim of our study is to assess whether our patients with Parkinson’s disease (PD) met recommended criteria to perform advanced therapy (AT) like…
  • 2024 International Congress

    Deep Brain Stimulation of the Subthalamic Nuclei in Advanced Parkinson’s Disease what Effects on Motor Non-motor and Neuropsychological Functions a Monocentric Prospective Study with a 12-month Follow-up

    V. Leclercq, B. Delsaut, V. Donckels, S. Dethy (Sint-Pieters-Leeuw, Belgium)

    Objective: The aim of the study is to assess the evolution of motor symptoms (MS), non-motor symptoms (NMS) and neuropsychological functions (NF) in Parkinson's disease…
  • 2024 International Congress

    Repurposing Anti-Gout Medications for the Treatment of Parkinson’s Disease

    R. Hughes, O. Bandmann, L. Ferraiuolo, H. Mortiboys (Sheffield, United Kingdom)

    Objective: To undertake a repurposing drug screen for Parkinson’s disease (PD) and further investigate the mechanism of action of top hits. To assess, in vivo,…
  • 2024 International Congress

    Simulated Space Gravity Recapitulates Parkinson’s Disease Pathology in Neural Cell Model

    V. Lentini, G. Uras, A. Manca, M. El Faqir, S. Lucas, A. Schapira, A. Pantaleo (Sassari, Italy)

    Objective: This investigation centers on the potential influence of microgravity on α-synuclein aggregation, a hallmark feature of Parkinson's disease (PD) characterized by the formation of…
  • « Previous Page
  • 1
  • …
  • 54
  • 55
  • 56
  • 57
  • 58
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Survey-Based study of marijuana used in Parkinson’s Disease patients
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley